Clinical trials: Diabetes Type I
Diabetes Mellitus, Type 1
Feasibility Trial Testing the Bionic Pancreas With ZP4207
The purpose of this study was to determine whether the Bionic Pancreas with ZP4207 (dasiglucagon*) was feasible to improve glycemic control in adults with type 1 diabetes mellitus.
- Trial name
- dasiglucagon (NCT02971228)
- Testing
- Insulin Lispro, ZP4207 (dasiglucagon), Glucagon
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Zealand Pharma
Type 1 Diabetes
Diabetic Retinopathy Candesartan Trials
The primary objective is to determine whether candesartan, compared to placebo reduces the incidence of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients without retinopathy.
- Trial name
- DIRECT (NCT00252733)
- Testing
- candesartan cilexetil
- Where
- 3 sites in Australia, Denmark
- Volunteers
- 5,238 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus (T1DM), High Level of Sugar (Glucose) in the Blood
A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
This Phase 3 study was designed to demonstrate the net benefit of sotagliflozin versus placebo in patients with Type 1 Diabetes (T1D).
- Trial name
- inTandem3 (NCT02531035)
- Testing
- Sotagliflozin
- Where
- 135 sites in United States, Argentina and 17 more
- Volunteers
- 1,405 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetes Mellitus, Type 1
YpsoPump Occlusion Detection Algorithm: Collection of Real-world Data for In-silico Evaluation of a New Software Algorithm to Refine Occlusion Detection in Subjects With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A common difficulty related to the insulin pumps are occlusions of the insulin infusion set (IIS). This study aims to evaluate the performance of a new software algorithm to detect catheter-occlusion in silico in order to refine…
- Trial name
- NCT05096325
- Testing
- YpsoPump® insulin pump system
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 40 people
- Sponsor
- mylife Diabetes Care AG
Diabetes Mellitus, Type 1
A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar
The study will look at how well insulin icodec controls blood sugar levels in participants who have never used it before. Participants with type 1 diabetes (T1D) will be treated with insulin icodec as prescribed to by their…
- Trial name
- NCT07160816
- Testing
- Insulin icodec
- Where
- 37 sites in Germany, Italy
- Volunteers
- 245 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1)
This will be a Phase 2b, multicenter, randomized, double blind, titration clinical study, evaluating the efficacy and safety in the HDV Insulin Lispro Group versus Insulin Lispro Group in patients with type 1 diabetes over a 26…
- Trial name
- ISLE-1 (NCT02794155)
- Testing
- HDV Insulin Lispro, Insulin LISPRO
- Where
- 21 sites in United States
- Volunteers
- 157 people
- Sponsor
- Diasome Pharmaceuticals
Type 1 Diabetes Mellitus, Type 1 Diabetes Mellitus with Hypoglycemia
A Pilot Study to Assess the Feasibility of a Novel Non-invasive Technology to Measure Changing Blood Glucose Levels in Adults with Type-1 Diabetes Mellitus
The primary aim of this study is to assess the feasibility of the Lab demo 1.0 and associated computational models to detect and track glucose changes noninvasively and transcutaneously in defined and dynamic states of glycemia.
- Conditions
- Type 1 Diabetes Mellitus, Type 1 Diabetes Mellitus with Hypoglycemia, Type 1 Diabetes Mellitus with Hyperglycemia
- Trial name
- NCT06097689
- Testing
- Lab Demo 1.0
- Where
- Switzerland
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Liom Health AG
Diabetes, Diabetes Mellitus, Type 1
First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.
The study is comparing the new medicine NNC9204-1513 with a standard therapy of glucagon (GlucaGen®). This is the first time NNC9204-1513 is given to humans.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT03444467
- Testing
- NNC9204-1513, Glucagon
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type I Diabetes
Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.
- Trial name
- NCT06964087
- Testing
- OPT101
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Op-T LLC
Type 1 Diabetes Mellitus
Feasibility Study Assessing The Ability Of An Insulin Pump-Controlling Algorithm To Minimize Hypoglycemia And Hyperglycemia In Patients With Type 1 Diabetes In A Clinical Research Setting
The purpose of this study is to evaluate the performance of an insulin pump controlling algorithm while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.
- Trial name
- NCT01401751
- Testing
- Hypoglycemia-Hyperglycemia Minimizer System
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Animas Corporation
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate efficacy and safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to…
- Trial name
- Onset® 5 (NCT02825251)
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- 92 sites in United States, Belgium and 7 more
- Volunteers
- 472 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 1
A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes
The addition of BioChaperone to insulin lispro may accelerate the onset and shorten the duration of action of insulin lispro due to facilitation of the absorption of the insulin after subcutaneous injection.
- Trial name
- NCT02146651
- Testing
- BioChaperone insulin lispro 0.2U/Kg, BioChaperone insulin lispro 0.1U/Kg, BioChaperone insulin lispro 0.4U/Kg
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Adocia
Type 2 Diabetes Mellitus
A Study to Evaluate the DDI of HSK7653 With Metformin
This is a Phase 1, single center, open-label, single arm, drug-drug interaction study of HSK7653 and metformin in Healthy Subjects.
- Trial name
- NCT06084156
- Testing
- HSK7653, Metformin
- Where
- China
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Diabetes Mellitus, Type 1
A Study to Look at How Safe Insulin NNC0471-0119 is and How it Works in People With Type 1 Diabetes Mellitus
This study is looking at the safety of the new medicine, insulin NNC0471-0119, its concentrations in the blood and effect on blood sugar for the treatment of type 1 diabetes.
- Trial name
- NCT04655690
- Testing
- NNC0471-0119, Fast-acting insulin aspart
- Where
- Austria
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus
The study involves a single injection of LY2963016 and a single injection of Lantus, on 2 separate occasions in participants with type I diabetes.
- Trial name
- NCT01600950
- Testing
- LY2963016, Lantus
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Insulin-Dependent
Efficacy Safety and Tolerability of Multiple Doses of Oshadi Icp (Oshadi Oral Insulin) in Patients With Type 1 Diabetes Mellitus - Phase II Clinical Study
Diabetes mellitus (DM) is a chronic disease of carbohydrate, fat, and protein metabolism caused by an absolute or relative deficiency of insulin, an anabolic hormone.
- Conditions
- Diabetes Mellitus, Insulin-Dependent, Type 1
- Trial name
- NCT01973920
- Testing
- Oshadi Icp
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Oshadi Drug Administration
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes
This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the absorption and effect in the body of NN1218 in subjects with type 1 and type 2 diabetes.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01121276
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare the within-subject variability of the pharmacokinetic profiles of insulin detemir and insulin glargine in children and adolescents with type 1 diabetes.
- Trial name
- NCT01497574
- Testing
- insulin detemir, insulin glargine
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Novo Nordisk A/S
Diabetes type1
Evaluation of Satisfaction Regarding Home Healthcare Provider (HHP) Management of Type 1 Diabetic Patients Using a Closed-loop Automatic Insulin Delivery System
SATURN study aims at evaluating Home Healthcare Provider (HHP) Management of type 1 diabetic patients using a closed-loop automatic insulin delivery system (or artificial pancreas), and specifically satisfaction and interactions…
- Trial name
- SATURN (NCT04635280)
- Testing
- any closed-loop automatic insulin delivery system (or artificial pancreas) European Conformity (CE)-marking
- Where
- 2 sites in France
- Volunteers
- 35 people
- Sponsor
- Air Liquide Santé International
Diabetes, Diabetes Mellitus, Type 1
A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function
This trial is conducted globally. The aim of this trial is to assess the clinical proof-of-principle of NNC0114-0006 and liraglutide on preservation of beta-cell function in adult subjects with newly diagnosed type 1 diabetes…
- Trial name
- NCT02443155
- Testing
- NNC0114-0006, liraglutide
- Where
- 108 sites in United States, Austria and 16 more
- Volunteers
- 308 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.